Skip to main content
Top
Published in: Clinical Rheumatology 3/2005

01-06-2005 | Case Report

OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key?

Authors: Paolo Manganelli, Nicola Giuliani, Pieranna Fietta, Cristina Mancini, Mirca Lazzaretti, Angela Pollini, Federico Quaini, Mario Pedrazzoni

Published in: Clinical Rheumatology | Issue 3/2005

Login to get access

Abstract

Hepatitis C-associated osteosclerosis (HCAO) is an impressive example of acquired diffuse osteosclerosis in adults, recently described in ten patients infected with hepatitis C virus (HCV). Its hallmark is a painful and generalized increase of bone mass. Bone biopsies show enhanced accretion rate, usually without histological abnormalities. The HCAO pathogenesis is hitherto unknown. HCV might induce a slow bone cell infection and the production of bone growth factors, such as insulin-like growth factors. Recently, receptor activator of nuclear factor-κB (RANK), its ligand (RANKL), and soluble decoy receptor osteoprotegerin (OPG) have been identified as a pivotal cytokine system in the bone remodeling control. We describe the 11th case of HCAO. Notably, the patient’s bone biopsy showed the presence of a high number of OPG-positive osteoblasts, a slight increase of RANKL-positive stromal cells, and a dramatic reduction of the osteoclasts. Moreover, OPG serum levels were increased. These findings reported here for the first time are consistent with a pathogenetic role of the OPG/RANKL system imbalance in HCAO.
Literature
1.
go back to reference Beyer HS, Parfitt AM, Shih MS, Anderson Q, Heath H (1990) Idiopathic acquired diffuse osteosclerosis in a young woman. J Bone Miner Res 5:1257–1263PubMed Beyer HS, Parfitt AM, Shih MS, Anderson Q, Heath H (1990) Idiopathic acquired diffuse osteosclerosis in a young woman. J Bone Miner Res 5:1257–1263PubMed
2.
go back to reference Villareal DT, Murphy WA, Teitelbaum SL, Arens MQ, Whyte MP (1992) Painful diffuse osteosclerosis after intravenous drug abuse. Am J Med 93:371–381CrossRefPubMed Villareal DT, Murphy WA, Teitelbaum SL, Arens MQ, Whyte MP (1992) Painful diffuse osteosclerosis after intravenous drug abuse. Am J Med 93:371–381CrossRefPubMed
3.
go back to reference Whyte MP, Murphy WA, Villareal DT, Teitelbaum SL, Arens MQ (1993) Diffuse osteosclerosis after intravenous drug abuse. Am J Med 95:661–662CrossRef Whyte MP, Murphy WA, Villareal DT, Teitelbaum SL, Arens MQ (1993) Diffuse osteosclerosis after intravenous drug abuse. Am J Med 95:661–662CrossRef
4.
go back to reference Whyte MP, Teitelbaum SL, Reinus WR (1996) Doubling skeletal mass during adult life: the syndrome of diffuse osteosclerosis after intravenous drug abuse. J Bone Miner Res 11:554–558PubMed Whyte MP, Teitelbaum SL, Reinus WR (1996) Doubling skeletal mass during adult life: the syndrome of diffuse osteosclerosis after intravenous drug abuse. J Bone Miner Res 11:554–558PubMed
5.
go back to reference Diamond T, Depczynsky B (1996) Acquired osteosclerosis associated with intravenous drug use and hepatitis C infection. Bone 19:679–683CrossRefPubMed Diamond T, Depczynsky B (1996) Acquired osteosclerosis associated with intravenous drug use and hepatitis C infection. Bone 19:679–683CrossRefPubMed
6.
go back to reference Whyte MP, Reasner CA II (1997) Hepatitis C-associated osteosclerosis after blood transfusion. Am J Med 102:219–220CrossRefPubMed Whyte MP, Reasner CA II (1997) Hepatitis C-associated osteosclerosis after blood transfusion. Am J Med 102:219–220CrossRefPubMed
7.
go back to reference Hassoun AAK, Nippoldt TB, Tiegs RD, Khosla S (1997) Hepatitis C-associated osteosclerosis: an unusual syndrome of acquired osteosclerosis in adults. Am J Med 103:70–73CrossRef Hassoun AAK, Nippoldt TB, Tiegs RD, Khosla S (1997) Hepatitis C-associated osteosclerosis: an unusual syndrome of acquired osteosclerosis in adults. Am J Med 103:70–73CrossRef
8.
go back to reference Shaker JL, Reinus WR, Whyte MP (1998) Hepatitis C-associated osteosclerosis: late onset after blood transfusion in an elderly woman. J Clin Endocrinol Metab 83:93–98CrossRefPubMed Shaker JL, Reinus WR, Whyte MP (1998) Hepatitis C-associated osteosclerosis: late onset after blood transfusion in an elderly woman. J Clin Endocrinol Metab 83:93–98CrossRefPubMed
9.
go back to reference Wakitani S, Hattori T, Nakaya H, Chae YM, Murata N, Tanigami A (2003) Clinical images: hepatitis C-associated osteosclerosis. Arthritis Rheum 48:268PubMed Wakitani S, Hattori T, Nakaya H, Chae YM, Murata N, Tanigami A (2003) Clinical images: hepatitis C-associated osteosclerosis. Arthritis Rheum 48:268PubMed
10.
go back to reference Khosla S, Hassoun AAK, Baker BK, Liu F, Zein NN, Whyte MP, et al (1998) Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis. Potential insights into increasing bone mass in adults. J Clin Invest 101:2165–2173PubMed Khosla S, Hassoun AAK, Baker BK, Liu F, Zein NN, Whyte MP, et al (1998) Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis. Potential insights into increasing bone mass in adults. J Clin Invest 101:2165–2173PubMed
11.
go back to reference Hofbauer LC, Heufelder AE (2001) Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology. J Mol Med 79:243–253CrossRefPubMed Hofbauer LC, Heufelder AE (2001) Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology. J Mol Med 79:243–253CrossRefPubMed
12.
go back to reference Giuliani N, Bataille R, Mancini C, Lazaretti M, Barillé S (2001) Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98:3527–3533CrossRefPubMed Giuliani N, Bataille R, Mancini C, Lazaretti M, Barillé S (2001) Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98:3527–3533CrossRefPubMed
13.
go back to reference Singer FR (1996) Paget’s disease of bone: possible viral basis. Trends Endocrinol Metab 7:258–261CrossRef Singer FR (1996) Paget’s disease of bone: possible viral basis. Trends Endocrinol Metab 7:258–261CrossRef
14.
go back to reference Shaker JL, Moore BP, Whyte MP (1999) Hyperparathyroidism and increased serum IGF-binding protein-2 levels in hepatitis C-associated osteosclerosis. J Clin Endocrinol Metab 84:384–385CrossRefPubMed Shaker JL, Moore BP, Whyte MP (1999) Hyperparathyroidism and increased serum IGF-binding protein-2 levels in hepatitis C-associated osteosclerosis. J Clin Endocrinol Metab 84:384–385CrossRefPubMed
15.
go back to reference Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R (1993) Anabolic actions of parathyroid hormone on bone. Endocr Rev 14:690–709CrossRefPubMed Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R (1993) Anabolic actions of parathyroid hormone on bone. Endocr Rev 14:690–709CrossRefPubMed
Metadata
Title
OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key?
Authors
Paolo Manganelli
Nicola Giuliani
Pieranna Fietta
Cristina Mancini
Mirca Lazzaretti
Angela Pollini
Federico Quaini
Mario Pedrazzoni
Publication date
01-06-2005
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 3/2005
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-004-1031-3

Other articles of this Issue 3/2005

Clinical Rheumatology 3/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine